id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-D-0605-0060,FDA,FDA-2011-D-0605,Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies; Draft Guidance for Industry,Other,Guidance,2025-11-20T05:00:00Z,2025,11,2025-11-20T05:00:00Z,2026-01-21T04:59:59Z,2026-01-24T13:16:32Z,,1,0,09000064b9088de2
FDA-2011-D-0605-0059,FDA,FDA-2011-D-0605,Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2025-11-20T05:00:00Z,2025,11,2025-11-20T05:00:00Z,,2025-11-20T19:15:15Z,2025-20380,0,0,09000064b908a856